CASI Pharmaceuticals annual stock-based compensation
2020
2021
2022
2023
2024
2025
CASI Pharmaceuticals Stock-Based Compensation Growth & History (CASIF)
CASI Pharmaceuticals's stock-based compensation was $3.0M for fiscal 2025.
View full CASI Pharmaceuticals company overviewCASI Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.0M | $1.7M | +128.64% |
| 2024 | 2024-12-31 | $1.3M | −$5.9M | −81.90% |
| 2023 | 2023-12-31 | $7.2M | $207,000 | +2.95% |
| 2022 | 2022-12-31 | $7.0M | −$760,000 | −9.78% |
| 2021 | 2021-12-31 | $7.8M | −$51,000 | −0.65% |
| 2020 | 2020-12-31 | $7.8M | — | — |
CASI Pharmaceuticals stock-based compensation trends
Over the last five fiscal years, CASI Pharmaceuticals's stock-based compensation decreased from $7.8M to $3.0M, a change of −$4.8M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CASI Pharmaceuticals source filings ↗